No photo of Silvia Damian

View Scopus Profile

Silvia Damian

20162019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Silvia Damian is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 12 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Combination of baseline LDH, performance status and age as integrated algorithm to identify solid tumor patients with higher probability of response to anti PD-1 and PD-l1 monoclonal antibodies

Cona, M. S., Lecchi, M., Cresta, S., Damian, S., Del Vecchio, M., Necchi, A., Poggi, M. M., Raggi, D., Randon, G., Ratta, R., Signorelli, D., Vernieri, C., de Braud, F., Verderio, P. & Di Nicola, M., Feb 2019, In : Cancers. 11, 2, 223.

Research output: Contribution to journal › Article

Open Access

    • Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study

    Mariani, G., Galli, G., Cavalieri, S., Valagussa, P., Bianchi, G. V., Capri, G., Cresta, S., Ferrari, L., Damian, S., Duca, M., de Braud, F. & Moliterni, A., Mar 1 2019, In : Breast Journal. 25, 2, p. 237-242 6 p.

    Research output: Contribution to journal › Article

    • A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

    Schöffski, P., Cresta, S., Mayer, I. A., Wildiers, H., Damian, S., Gendreau, S., Rooney, I., Morrissey, K. M., Spoerke, J. M., Ng, V. W., Singel, S. M. & Winer, E., Sep 5 2018, In : Breast Cancer Research. 20, 1, p. 109

    Research output: Contribution to journal › Article

    • Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study

    Cohen, R. B., Delord, J-P., Doi, T., Piha-Paul, S. A., Liu, S. V., Gilbert, J., Algazi, A. P., Damian, S., Hong, R-L., Le Tourneau, C., Day, D., Varga, A., Elez, E., Wallmark, J., Saraf, S., Thanigaimani, P., Cheng, J. & Keam, B., Feb 21 2018, In : American Journal of Clinical Oncology.

    Research output: Contribution to journal › Article

    • Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1)

    Drilon, A., Siena, S., Ou, S. H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., Doebele, R., Giannetta, L., Cerea, G., Marrapese, G., Schirru, M., Amatu, A., Bencardino, K., Palmeri, L., Sartore-Bianchi, A., Vanzulli, A. & 15 others, Cresta, S., Damian, S., Duca, M., Ardini, E., Li, G., Christiansen, J., Kowalski, K., Johnson, A. D., Patel, R., Luo, D., Chow-Maneval, E., Hornby, Z., Multani, P. S., Shaw, A. T. & De Braud, F. G., Apr 1 2017, In : Cancer Discovery. 7, 4, p. 400-409 10 p.

    Research output: Contribution to journal › Article